Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Regeneron Pharmaceuticals    REGN

REGENERON PHARMACEUTICALS (REGN)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles

Regeneron shares poised for rebound: Barron's

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/07/2017 | 07:19pm CEST

(Reuters) - Shares of Regeneron Pharmaceuticals Inc, which tumbled 32 percent in 2016, are poised for a rebound, the financial newspaper Barron's said.

A better-than-expected launch of Regeneron's skin treatment Dupixent caused shares to soar last week, the paper reported in its May 8 edition. If Dupixent usage grows faster than expected, it could take pressure off Regeneron's other drugs, including eye drug Eylea, Barron's said.

Regeneron said that 900 prescriptions had been written for Dupixent and that the number of doctors prescribing the drug had jumped by nearly 50 percent.

(Reporting by Olivia Oran; Editing by Phil Berlowitz)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on REGENERON PHARMACEUTICALS
06/20TODAY'S RESEARCH REPORTS ON TRENDING : Regeneron Pharmaceuticals and Intrexon
AC
06/20REGENERON PHARMACEUTICALS : Decibel raises $55M in series C, names Scangos chair..
AQ
06/20Latecomer Sanofi looks to catch next wave of cancer therapies
RE
06/19NASDAQ 100 MOVERS : Jd, regn
AQ
06/14REGENERON PHARMACEUTICALS : Researchers from Regeneron Pharmaceuticals Provide D..
AQ
06/14REGENERON PHARMACEUTICALS : and Zoetis Announce Collaboration to Research Antibo..
AQ
06/13REGENERON PHARMACEUTICALS INC : Submission of Matters to a Vote of Security Hold..
AQ
06/13Sanofi says on track to regain solid position in cancer drugs
RE
06/11REGENERON : Back Above $300
AQ
06/11REGENERON PHARMACEUTICALS : Report
CO
More news
News from SeekingAlpha
06/243 THINGS IN BIOTECH, JUNE 23 : Regeneron Spiders Out With Inovio, Synairgen Prov.. 
06/23VENTURE CAPITAL DEALS OF THE WEEK : Tencent Bets On Online Education 
06/23What Does Breakthrough Therapy Designation Really Mean For My Company? 
06/223 THINGS IN BIOTECH, JUNE 21 : Regeneron Sneaks Up In The Kidney Cancer Space 
06/22Sell Kraft-Heinz At $64-65 - Cramer's Lightning Round (6/21/18) 
Financials ($)
Sales 2018 6 321 M
EBIT 2018 2 525 M
Net income 2018 1 807 M
Finance 2018 3 194 M
Yield 2018 -
P/E ratio 2018 21,52
P/E ratio 2019 19,31
EV / Sales 2018 5,06x
EV / Sales 2019 4,24x
Capitalization 35 172 M
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals Technical Analysis Chart | REGN | US75886F1075 | 4-Traders
Technical analysis trends REGENERON PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 25
Average target price 374 $
Spread / Average Target 13%
EPS Revisions
Managers
NameTitle
Leonard S. Schleifer Co-President, Chief Executive Officer & Director
George Damis Yancopoulos Co-President, Director & Chief Scientific Officer
P. Roy Vagelos Chairman
Robert E. Landry Chief Financial Officer & Senior VP-Finance
Michael S. Brown Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
REGENERON PHARMACEUTICALS-11.70%35 172
GILEAD SCIENCES-0.80%92 410
VERTEX PHARMACEUTICALS3.10%40 566
GENMAB-3.97%9 557
SAREPTA THERAPEUTICS INC152.21%9 196
NEUROCRINE BIOSCIENCES, INC.31.19%9 151